SurBred

SurBred is a sublingual tablet formulation of sufentanil citrate, a highly potent synthetic opioid analgesic. Developed for the management of moderate-to-severe acute pain in a medically supervised setting, it utilizes a specialized delivery system to administer the drug via the oral mucosa. Sufentanil acts as a selective agonist at the mu-opioid receptor, providing analgesic effects significantly more potent than fentanyl or morphine. By utilizing the sublingual route, SurBred achieves rapid systemic absorption and avoids first-pass hepatic metabolism, offering a non-invasive alternative to intravenous opioid administration. The product was originally developed by AcelRx Pharmaceuticals (now Talphera) and is licensed to Yichang Humanwell Pharmaceutical for the Chinese market.

Brand names

SurBredDsuvia

Other names

sufentanil sublingual tabletsufentanil citrate